- Home
- HPQ vs RPRX Comparison
HPQ vs RPRX Comparison
Compare HPQ & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HPQ | RPRX |
|---|---|---|
| Founded | 1939 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.3B | 19.5B |
| IPO Year | 2002 | 2020 |
Fundamental Metrics
Financial Performance| Metric | HPQ | RPRX |
|---|---|---|
| Price | $19.37 | $48.54 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 4 |
| Target Price | $21.42 | ★ $47.75 |
| AVG Volume (30 Days) | ★ 16.7M | 2.8M |
| Earning Date | 02-24-2026 | 05-07-2026 |
| Dividend Yield | ★ 6.15% | 1.94% |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.58 | ★ 1.78 |
| Revenue | ★ $55,295,000,000.00 | $2,378,193,000.00 |
| Revenue This Year | $3.10 | $38.30 |
| Revenue Next Year | $0.39 | $4.80 |
| P/E Ratio | $33.59 | ★ $27.29 |
| Revenue Growth | 3.24 | ★ 5.06 |
| 52 Week Low | $17.56 | $29.66 |
| 52 Week High | $29.55 | $49.06 |
Technical Indicators
Market Signals| Indicator | HPQ | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 55.94 | 70.10 |
| Support Level | $17.96 | $35.32 |
| Resistance Level | $20.09 | N/A |
| Average True Range (ATR) | 0.72 | 0.89 |
| MACD | 0.10 | 0.17 |
| Stochastic Oscillator | 70.43 | 88.68 |
Price Performance
Historical ComparisonAbout HPQ HP Inc.
HP (formerly Hewlett-Packard) is a behemoth in the PC and printing markets. It has focused on these markets since it exited IT infrastructure in 2015 with the split from Hewlett Packard Enterprise. HP focuses on the commercial market, but maintains sales of consumer devices and printers. The firm has a broad and global customer base, with only one third of sales coming from the US. HP completely outsources manufacturing and relies heavily on channel partners for its sales and marketing.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.